Joel W. Neal, Byoung Chul Cho, Yongsheng Wang, Lin Wu, Enriqueta Felip, Jiuwei Cui, Alexander I. Spira, Melina Elpi Marmarelis, Eiki Ichihara, Se-Hoon Lee, James Chih Hsin Yang, Sebastian Yves Friedrich Michels, Joshua C. Curtin, Xuesong Lu, Zacharias Anastasiou, Isabelle Leconte, Leonardo Trani, Sujay Shah, Pascale Tomasini. "Overall survival of first-line amivantamab plus lazertinib in atypical
                    <i>EGFR</i>
                    -mutated advanced non-small cell lung cancer (NSCLC): Updated results from the CHRYSALIS-2 study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.8501